科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Molecular Pharmaceutics2025-10-08· Bioavailability

Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies

Hélène Pereira, Stefan Wölke, Behbood Sadrolhefazi, Habib Esmaeili, Sven Wind, Guanfa Gan, Fabian Müller, David Minich, Kerstin Bader, Rolf Grempler, Yeuk Ki Law, Philipp M. Roessner

原始摘要(英文原文)· Original abstract
High Resolution Image Download MS PowerPoint Slide Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is mutated in various solid tumors. Zongertinib (BI 1810631) is a novel, orally administered, HER2-specific tyrosine kinase inhibitor that spares the epidermal growth factor receptor (EGFR), limiting EGFR-related adverse events. Zongertinib has recently received accelerated approval in the United States and China for patients with advanced, previously treated, HER2 mutant NSCLC. Two Phase I open-label crossover studies evaluated the effect of a high-fat, high-calorie meal on zongertinib bioavailability at two doses: 30 mg (NCT05380947) and 240 mg (NCT06075277). Healthy male participants were randomized to treatment sequences in which they received single doses of zongertinib (spray-dried dispersion formulations) under fed and fasted conditions. The washout interval was ≥14 days. The primary end points were the area under the concentration–time curve of zongertinib in plasma over the time from 0 to the last quantifiable data point (AUC 0-tz ), and the maximum measured concentration of zongertinib in plasma ( C max ). In NCT05380947, 13 participants received 30 mg of zongertinib. The ratios of adjusted geometric means demonstrated lower AUC 0-tz and C max, under fed ( n = 9) versus fasted ( n = 12) conditions (fed/fasted, % [90% CI]: AUC 0-tz, 74.2% [67.6–81.6]; C max, 53.5% [40.5–70.8]). In NCT06075277, the ratios of adjusted geometric means for AUC 0-tz and C max were ∼26% higher under fed versus fasted conditions (fed/fasted, % [90% CI]: AUC 0-tz, 126.6% [112.1–143.1]; C max, 126.1% [106.3–149.6]). In both studies, median t max was delayed (NCT05380947/NCT06075277) under fed (3/4 h) versus fasted (1.5/2 h) conditions. Zongertinib demonstrated good bioavailability in healthy participants. A small dose-dependent food effect was observed.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies — 科研速览 Science Skim